Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
More loons are filling Maine's lakes with their ghostlike calls - 2Vote In favor of Your Favored Sort Of Dress
- 3Shadow Cats: The Elusive Leopards Surviving Against Impossible Odds
- 4Flu season is underway. What are common symptoms to watch for?
- 5A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Wonderful Sea shores All over the Planet
- US measles cases surpass 2,000, highest in 30 years: CDC
- Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- Extraordinary Shows to Long distance race on a Plane
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
